The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum resistant ovarian cancer (OC).
- 20 May 2017
- journal article
- gynecologic cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl), 5560
- https://doi.org/10.1200/jco.2017.35.15_suppl.5560